We also engineered NDV to express a soluble version of the murine PD-1 receptor to block both PD-L1 and PD-L2, which are often expressed on tumor cells and other TILs, from binding PD-1 receptors on CTLs and rendering them dysfunctional. Here, CD274 is linked to neoplasm.